Table 4.
Therapy and mortality of patients with Pseudomonas aeruginosa producing metallo-β-lactamase hospital-acquired pneumonia
| Treatment | Hospital-acquired pneumonia (n = 42) | Ventilator-associated pneumonia (n = 22) | ||
| Treated patients | 30-day mortality (n = 24) | Treated patients | 30-day mortality (n = 17) | |
| Appropriate monotherapy | 18 (42.9) | 9 (50.0) | 12 (54.5) | 9 (75.0) |
| Aztreonama | 8 | 2 | 3 | 2 |
| Polymyxin Bb | 6 | 4 | 5 | 4 |
| Piperacillin-tazobactamc | 4 | 3 | 4 | 3 |
| Appropriate combination therapy | 3 (7.1) | 0 (0.0) | 1 (4.5) | 0 (0.0) |
| Polymyxin B + aztreonam | 2 | 0 | 1 | 0 |
| Aztreonam + amikacin | 1 | 0 | - | - |
| Nonappropriate combination therapy | 3 (7.1) | 2 (66.7) | 1 (4.5) | 0 |
| Aztreonam + ceftazidime + amikacin | 1 | 1 | - | - |
| Imipenem + ceftazidime | 1 | 0 | 1 | 0 |
| Imipenem + ciprofloxacin | 1 | 1 | - | - |
| Nonappropriate monotherapy | 17 (40.5) | 12 (70.6) | 8 (36.4) | 8 (100) |
| Cefepime | 7 | 5 | 3 | 3 |
| Meropenem | 6 | 3 | 2 | 2 |
| Imipenem | 2 | 2 | 2 | 2 |
| Ceftazidime | 1 | 1 | 1 | 1 |
| Amikacin | 1 | 1 | - | - |
| Without therapy | 1 (2.4) | 1 (100) | - | - |
aThe association of in vitro nonsusceptible antibiotics were used in three patients: ceftazidime (one patient), cefepime (one patient), and ceftazidime + amikacin (one patient); all were survivors. bOne patient received the association of cefepime (in vitro nonsusceptible); survivor. cOne patient received the association of ciprofloxacin (in vitro nonsusceptible); nonsurvivor.